Review highlights biological heterogeneity in triple-negative breast cancer and its implications for treatment.
Triple-negative breast cancer (TNBC) is commonly approached as a single clinical entity despite marked biological heterogeneity. A subset of cases corresponds to rare histologic subtypes that display distinct molecular drivers, immune microenvironments, and clinical behavior. In this Review, we summarize the clinicopathologic and molecular features of rare TNBC histologies and discuss emerging therapeutic vulnerabilities. Integrating histologic classification with molecular profiling may enable more precise risk stratification and guide biomarker-driven treatment strategies.
No takes yet. Share an insight, caveat, or question.
Gouveia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: